TRINOMAB
- Biotech or pharma, therapeutic R&D
With its first-in-class, a breakthrough next generation product Sintetol i.e. anti-tetanus antibody approval & launch in 2025, Trinomab has grown into a biopharmaceutical company that is dedicated to pioneering the discovery, development and commercialization of fully native human monoclonal antibodies with added values for patients in need.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}